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Background
TriMixDC-MEL consists of autologous monocyte-derived
DC that are electroporated with synthetic mRNA encod-
ing CD40 ligand, a constitutively active TLR4, CD70 and
fusion proteins of DC.LAMP with 4 melanoma associated
antigens (MAGE-A3, MAGE-C2, tyrosinase and gp100).
Methods
TriMixDC-MEL was investigated in patients (pts) with
pretreated advanced melanoma, either as a single agent
(Phase Ib; NCT01066390) or combined with IPI (Phase II;
NCT01302496; 10 mg/kg q3wks x4) and also in melanoma
pts who are disease free following local treatment of
macrometastases. TriMixDC-MEL was administered by
the IV and ID-route (4 to 5 admin; 4.106-ID/20.106-IV).
Results
In pts with unresectable AJCC stage III or IV mela-
noma, respectively 15 and 39 pts were treated in the
Phase Ib and the –II trial. DC-related AEs consisted of
local inflammatory skin reactions at the DC-injection
site (all pts), grade (gr) 2 acute post-IV injection chills
in 20% and 38%, and gr 1-2 flu-like syndrome in 53%
and 85% of pts treated respectively with DC or DC+IPI.
Grade 3 or 4 irAEs occurred in 36% of DC+IPI treated
pts. ORR for DC: 27% (2 CR, 2 PR; 3 are ongoing after
> +51 mths) and 38% for DC+IPI (8 CR, 7 PR; 8 are
ongoing after > +16, mths). Median PFS and OS are
respectively 5 (95% CI 0–10) and 14 mths (95% CI
5–23) for DC and 6.2 (95% CI 2-10) and 13 mths (95%
CI, 9-18) for DC+IPI. The 1, 2 and 3y OS% for DC+IPI
were: 59% (95% CI 43-74), 38% (95% CI, 23-53), and
34% (95% CI, 19-50). Treatment with TriMixDC-MEL,
especially in combination with IPI, is tolerable and
results in a high rate of durable tumor responses. In the
adjuvant setting (NCT01676779), 41 patients were rando-
mized between the TriMixDC-MEL treatment arm (n=21)
and control-arm (n=20). Baseline characteristics were well
balanced between both groups. After a median follow-up
of 18 mths (range 5 to 30 mths) 20 patients experienced a
non-salvageable melanoma recurrence (6 on the DC- and
14 on the control-arm). The rate of patients who were dis-
ease-free at 1 year (evaluable population = 35 patients)
was higher in the TriMixDC-MEL treated group (65%
[95%CI 42-87] vs. 34% [13-55]). TriMixDC-MEL was well
tolerated (no grade >3 AE).
Conclusions
The results of this non-comparative randomized controlled
Phase II clinical trial of TriMixDC-MEL ID/IV versus
observation support the further evaluation of TriMixDC-
MEL as a well-tolerated adjuvant therapy for melanoma
patients following the resection of macrometastases.
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